TRDA
Entrada Therapeutics, Inc.BS score 46.4MEDIUMPHASE2 · mkt cap $537.9M · rev ttm $25.4M
drug hypothesis
Information not provided - SEC filing content appears incomplete (only '9' provided) modulates Information not provided to treat MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) - derived from clinical trial data only.
moa:Information not provided
score breakdown
trial design55
base rate disconnect21
language red flags80
composite46.4
valuation analysis
market cap$537.9M
revenue ttm$25.4M
phasePHASE2
historical base rate15%
disconnect ratio0.7x
lead trialNCT04245917
meta
cik0001689375
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
NCT04245917 is a SUSPENDED natural history (observational) study, not an interventional drug trial. Non-randomized, none placebo-controlled. Enrollment: 60 patients. Start: 2020-08-06, Primary completion: 2025-02. No therapeutic intervention listed.
primary endpoint:MNGIE Clinical Course (5 years) - from NCT04245917
claimed differentiation
Information not provided in filing
language red flags
- SEC filing section contains only '9' - appears incomplete or placeholder text
- Clinical trial is SUSPENDED with no clear explanation
- Natural history study provides no efficacy data for any therapeutic candidate
- No company or drug candidate identified in provided data
company-stated risks
- Information not provided